Integra LifeSciences Holdings (IART) Q1 2026 Earnings Snapshot

Integra LifeSciences Holdings (IART) has opened 2026 with Q1 results that sit against a backdrop of recent quarterly revenue between US$380.7 million and US$442.6 million and EPS swinging from a profit of US$0.25 in Q4 2024 to a loss of US$6.31 in Q2 2025 and US$0.02 in Q4 2025. Trailing 12 month EPS stands at a loss of US$6.74 on revenue of about US$1.6 billion. Over the past six reported quarters, revenue has ranged from US$380.8 million to US$442.6 million and trailing 12 month revenue has moved between US$1.56 billion and US$1.64 billion, while EPS has shifted from a small loss of US$0.09 on a trailing basis in Q4 2024 to a much larger loss of US$6.74 in Q4 2025. In this context, the latest numbers keep the spotlight firmly on margins and on how quickly the business can move profitability back toward breakeven.

See our full analysis for Integra LifeSciences Holdings.

With the headline figures on the table, the next step is to line these results up against the widely followed narratives around Integra LifeSciences Holdings to see which stories the numbers support and which they call into question.

Losses stack up on trailing US$516 million net loss

• Over the last twelve months, Integra LifeSciences has booked a net loss of about US$516.5 million on US$1.64 billion of revenue, with trailing EPS at a loss of US$6.74. This shows that profitability is currently a key weak spot rather than a short blip.
• Consensus narrative talks about margins recovering to 4.9% and earnings reaching US$90.9 million. That sits against:
  • Trailing losses that have grown at roughly a 74.5% annual rate over the past five years, which is very different from the improvement analysts are modelling.
  • Current trailing margins that are deeply negative, so the path from a US$516.5 million loss to positive earnings is long and relies heavily on the operational and cost improvements analysts expect.

Revenue growth at 3.5% while market runs faster

• Revenue growth is forecast at 3.5% per year, which is slower than the 11.2% per year forecast for the broader US market. Even if sales keep ticking up, the company is not expected to keep pace with the wider opportunity set.
• Bulls argue that supply chain fixes and product relaunches could support stronger growth, but the current figures pull both ways:
  • Trailing twelve month revenue has been fairly steady, sitting in a band of roughly US$1.56 billion to US$1.64 billion. This leaves room for bulls to argue that stabilised operations could help regain lost ground.
  • At the same time, the 3.5% revenue growth forecast is only slightly above the more cautious 3.2% revenue growth assumption in the bearish view, so both sides are working off relatively modest top line expectations compared with the wider market.

On the bullish side, supporters point to a potential earnings turnaround even from today’s large loss base. This is a big swing investors need to be comfortable with before leaning into that story. 🐂 Integra LifeSciences Holdings Bull Case

Unprofitable with weak interest cover despite low 0.6x P/S

• The stock trades on a P/S of 0.6x versus 2.8x for the US Medical Equipment industry and 4.1x for peers, yet the company is unprofitable on a trailing basis and interest payments are not well covered by earnings. This underlines that the low multiple comes with real financial risk attached.
• Bears highlight that rising losses and poor interest coverage can outweigh any apparent valuation discount, and the trailing data lines up with that concern:
  • Trailing EPS has moved from a small loss of US$0.09 in Q4 2024 to a much larger loss of US$6.74 by Q4 2025, while trailing net losses have widened to more than US$500 million. This fits the cautious view on earnings quality.
  • With earnings not covering interest over the last twelve months, leverage and financing costs remain pressure points that can limit flexibility even if revenue holds around the current US$1.6 billion level.

For readers focused on the risks around leverage and profitability, the bear case is built directly off these weak trailing earnings and coverage metrics. 🐻 Integra LifeSciences Holdings Bear Case

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Integra LifeSciences Holdings on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

With sentiment clearly mixed across earnings, margins, and balance sheet strength, it makes sense to move quickly and test the numbers against your own expectations. To see how the risk and reward signals stack up in one place, take a closer look at the 2 key rewards and 1 important warning sign

See What Else Is Out There

Integra LifeSciences is working with large losses, weak interest cover, and only modest revenue growth forecasts compared with the broader US market.

If those risks feel a bit heavy, you can quickly compare this situation with companies that score better on financial resilience by checking the 72 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.